In the 1970s, an unknown virus was suspected for documented cases of transfusion-
associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious …

Background: Rapid improvements in hepatitis C virus (HCV) therapy have led to the
approval of multiple oral direct-acting antiviral (DAA) regimens by the US Food and Drug …

The first human orthotopic liver transplantation (LT) in Europe was performed by Sir Roy
Calne in Cambridge in 1968 [1], only one year after the first successful human liver …

Background & Aims There are no effective and safe treatments for chronic hepatitis C virus
(HCV) infection of patients who have advanced liver disease. Methods In this phase 2, open …

Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post‐liver
transplantation recurrence represents a high unmet medical need with no approved …

The hepatitis C virus (HCV) was discovered in the late 1980s. Interferon (IFN)-α was
proposed as an antiviral treatment for chronic hepatitis C at about the same time. Successive …

The field of HCV therapeutics continues to evolve rapidly and since the World Health
Organization (WHO) issued its first Guidelines for the screening care and treatment of …

Nirmatrelvir/ritonavir (NR) use has not yet been described in solid organ transplant
recipients (SOTRs) with mild COVID‐19. The objective was to evaluate outcomes among …

Patients with hepatitis C virus (HCV) genotype 3 infection, especially those with advanced
liver disease, are a challenging population in urgent need of optimally effective therapies …

Well‐tolerated, ribavirin‐free, pangenotypic hepatitis C virus (HCV) treatments for transplant
recipients remain a high priority. Once‐daily glecaprevir/pibrentasvir demonstrates high …